Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78306358 in Advanced Stage Solid Tumors
NCT04991740Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of jnj-78306358 in renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC) and 1 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Incidence of Adverse Events, Number of Participants with AEs by Severity and 1 more. Started Oct 2021; status: completed.
02
Drugs
jnj-78306358
03
Conditions
renal cell carcinoma (RCC)ovarian cancercolorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT04991740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991740.